The Journal of Immunology, Vol 143, Issue 1 59-65, Copyright © 1989 by American Association of Immunologists

ARTICLES

Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fc gamma RII, and B220 molecules on murine splenic B cells

DP Snider and DM Segal
Experimental Immunology Branch, National Cancer Institute, Bethesda, MD 20892.

Bispecific heteroconjugate antibodies can bind soluble protein Ag to APC and thereby enhance Ag presentation. We used such antibodies to bind hen egg lysozyme (HEL) to various structures on the surface of normal splenic B cells to determine which structures would provide the best targets for enhanced presentation. We found that HEL was presented efficiently to hybridoma T cells if bound to sIgD, sIgM, or class I or II MHC molecules, but not at all if bound to Fc gamma RII, or B220 molecules on B cells. The efficiency of presentation of HEL was measured as a function of the amount of 125I-HEL bound per cell. HEL was presented with 5 to 10 times greater efficiency when bound to sIg, than when bound to MHC molecules. When compared on the basis of the amount of HEL bound, sIgD and sIgM functioned equally as target structures, as did class I and class II MHC molecules. Large amounts of HEL bound to B220, but no presentation resulted, indicating that focusing HEL to the APC surface was not sufficient for presentation to occur. HEL was internalized rapidly and in large amounts when bound to sIgD or sIgM, but slowly and in small amounts, when bound to class I or class II MHC molecules. Thus, a rapid rate of internalization may in part explain the high efficiency of Ag presentation after binding to sIg. However, the small amount of HEL internalized via MHC molecules was utilized efficiently for presentation. These results indicate that sIgM and sIgD serve equally on normal B cells to focus and internalize Ag and enhance Ag presentation, but that class I or class II MHC molecules can also be used to internalize Ag and enhance Ag presentation, perhaps by a separate intracellular processing pathway.

This article has been cited by other articles:

				U. Wahl, E. Nossner, K. Kronenberger, R. Gangnus, H. Pohla, M. S. Staege, H.-J. Kolb, M. Hallek, and R. Mocikat Vaccination against B-cell Chronic Lymphocytic Leukemia with Trioma Cells: Preclinical Evaluation Clin. Cancer Res., September 15, 2003; 9(11): 4240 - 4246. [Abstract] [Full Text] [PDF]

				K. Kronenberger, A. Dieckmann, M. Selmayr, J. Strehl, U. Wahl, H. Lindhofer, G. Kraal, and R. Mocikat Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells Blood, February 15, 2002; 99(4): 1327 - 1331. [Abstract] [Full Text] [PDF]

				L. Agren, E. Sverremark, L. Ekman, K. Schon, B. Lowenadler, C. Fernandez, and N. Lycke The ADP-Ribosylating CTA1-DD Adjuvant Enhances T Cell-Dependent and Independent Responses by Direct Action on B Cells Involving Anti-Apoptotic Bcl-2- and Germinal Center-Promoting Effects J. Immunol., June 15, 2000; 164(12): 6276 - 6286. [Abstract] [Full Text] [PDF]

				M. Leonetti, R. Thai, J. Cotton, S. Leroy, P. Drevet, F. Ducancel, J. C. Boulain, and A. Menez Increasing Immunogenicity of Antigens Fused to Ig-Binding Proteins by Cell Surface Targeting J. Immunol., April 15, 1998; 160(8): 3820 - 3827. [Abstract] [Full Text] [PDF]